Prospective practice survey of management of cetuximab-related skin reactions
| Autor: | Petronella O. Witteveen, C.M.L. van Herpen, C. del Grande, A.N.M. Wymenga, B. van Doorn, J. J. Koldenhof, Hans Gelderblom, Chantal M. L. Driessen, Ann Hoeben, Christine B. Boers-Doets, J. W. B. de Groot, R. T. Lugtenberg |
|---|---|
| Přispěvatelé: | RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Medische Oncologie (9) |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty medicine.drug_class Colorectal cancer Antibiotics Cetuximab Skin reaction Skin Diseases TOXICITY 03 medical and health sciences 0302 clinical medicine Antineoplastic Agents Immunological Quality of life QUALITY-OF-LIFE Internal medicine Surveys and Questionnaires medicine Clinical endpoint Humans HEAD Prospective Studies Head and neck cancer 030304 developmental biology PLUS CETUXIMAB 0303 health sciences business.industry Middle Aged medicine.disease Management METASTATIC COLORECTAL-CANCER Oncology 030220 oncology & carcinogenesis Observational study TRIAL Original Article Female business medicine.drug Rare cancers Radboud Institute for Health Sciences [Radboudumc 9] |
| Zdroj: | Supportive Care in Cancer Supportive Care in Cancer, 29, 7, pp. 3497-3506 Supportive Care in Cancer, 29(7), 3497-3506. Springer, Cham Supportive Care in Cancer, 29, 3497-3506. SPRINGER Supportive Care in Cancer, 29, 3497-3506 |
| ISSN: | 1433-7339 0941-4355 |
| Popis: | Purpose Evidence-based guidelines on how to prevent or treat cetuximab-related skin reactions are lacking and multiple care and management strategies are used. The main purpose of the present study is to gain information about the different skincare products being used against skin reactions in metastatic colorectal cancer (mCRC) and recurrent/metastatic (R/M) or locally advanced (LA) squamous cell cancer of the head and neck (SCCHN) patients treated with cetuximab. Methods An open-label, prospective observational study conducted in the Netherlands. The occurrence of skin reactions and the care and management options taken were documented for 16 weeks, starting from the first administration of cetuximab. Results A total of 103 patients were included in 7 hospitals. 38 patients (37%) developed a grade ≥ 2 skin reaction. Eighty-six patients could be analysed for the primary endpoint (73.3% males, mean age 62.4 years, n = 44 LA SCCHN, n = 16 R/M SCCHN, n = 26 mCRC). The most frequently used skin products at some point during the observation period were moisturizing products (70%), systemic antibiotics (64%), topical antibiotics (58%), lipid-regenerating (28%) and other topical products (28%). The overall use of products gradually increased from baseline to week 6–10, reducing by week 16. Hospital protocols were the primary reason (> 50%) for choice of the skincare products and medications. Conclusion A variety of skin care products and antibiotics were commonly used. Only few patients developed severe cutaneous reactions. For patients, the occurrence of skin reactions did not influence their willingness to continue cetuximab therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink